Investments and Fair Value Measurements - Narrative (Details)				3 Months Ended						9 Months Ended
	Jan. 02, 2020 USD ($)	Apr. 25, 2019	Nov. 01, 2018 USD ($) $ / shares	Oct. 03, 2021 USD ($)	Apr. 04, 2021 USD ($)	Sep. 27, 2020 USD ($)	Mar. 31, 2020 USD ($)	Mar. 29, 2020 USD ($)	Dec. 29, 2019 USD ($)	Oct. 03, 2021 USD ($) fund	Sep. 27, 2020 USD ($)	Jul. 04, 2021 USD ($)	Feb. 28, 2021 USD ($)	Jan. 03, 2021 USD ($)
Schedule of Investments [Line Items]
Marketable equity securities				$ 185,000,000						$ 185,000,000				$ 376,000,000
Marketable equity securities unrealized (losses) and gains				45,000,000		$ 59,000,000				(16,000,000)	$ 128,000,000
Gains (losses) on marketable equity securities				0						(7,000,000)	0
Strategic equity investments, without readily determinable fair values				61,000,000						$ 61,000,000				314,000,000
Number of venture capital investment funds | fund										2
Equity method investments				172,000,000						$ 172,000,000				104,000,000
Gain on Helix contingent value right										30,000,000	5,000,000
(Gain) loss on derivative assets related to terminated acquisition										26,000,000	(116,000,000)
Change in fair value of contingent consideration										(7,000,000)	0
Pacific Biosciences of California, Inc (PacBio)
Schedule of Investments [Line Items]
Cash			$ 1,200,000,000				$ 34,000,000	$ 132,000,000	$ 18,000,000
Share price (in dollars per share) | $ / shares			$ 8.00
Loss on contract termination	$ 98,000,000
Business combination, contingent consideration arrangements, maximum outcome	52,000,000
Equity or debt financing to be raised	$ 100,000,000
Derivative assets related to terminated acquisition								40,000,000
Pacific Biosciences of California, Inc (PacBio) | Selling, General and Administrative
Schedule of Investments [Line Items]
(Gain) loss on derivative assets related to terminated acquisition								$ (92,000,000)
Pacific Biosciences of California, Inc (PacBio) | Other Operating Income (Expense)
Schedule of Investments [Line Items]
Unrealized loss on derivatives						(10,000,000)					(25,000,000)
Series of Individually Immaterial Business Acquisitions
Schedule of Investments [Line Items]
Contingent consideration liabilities				15,000,000						15,000,000		$ 14,000,000
Change in fair value of contingent consideration				(1,000,000)						(1,000,000)
Helix Holdings I, LLC
Schedule of Investments [Line Items]
Contingent value right, terms		7 years
Gain on Helix contingent value right				12,000,000						30,000,000	5,000,000
Pacific Biosciences of California, Inc (PacBio) | S B Northstar L P
Schedule of Investments [Line Items]
Business combination, contingent consideration arrangements, maximum outcome													$ 52,000,000
(Gain) loss on derivative assets related to terminated acquisition					$ 26,000,000
Pacific Biosciences of California, Inc (PacBio) | S B Northstar L P | Convertible Senior Notes
Schedule of Investments [Line Items]
Principal amount of notes outstanding													$ 900,000,000
Venture Capital Investment Fund (the Fund)
Schedule of Investments [Line Items]
Commitment in new venture capital investment fund				100,000,000						100,000,000
Remaining capital commitment				23,000,000						23,000,000
Second Venture Capital Investment Fund
Schedule of Investments [Line Items]
Commitment in new venture capital investment fund				150,000,000						150,000,000
Remaining capital commitment				122,000,000						122,000,000
Investee
Schedule of Investments [Line Items]
Revenue from transactions with strategic investees				$ 14,000,000		$ 16,000,000				$ 47,000,000	$ 39,000,000
Variable Interest Entity, Not Primary Beneficiary | GRAIL
Schedule of Investments [Line Items]
Net assets														$ 250,000,000